CN113811301A - 使用布鲁顿酪氨酸激酶抑制剂治疗舍格伦综合征的方法 - Google Patents

使用布鲁顿酪氨酸激酶抑制剂治疗舍格伦综合征的方法 Download PDF

Info

Publication number
CN113811301A
CN113811301A CN202080032174.XA CN202080032174A CN113811301A CN 113811301 A CN113811301 A CN 113811301A CN 202080032174 A CN202080032174 A CN 202080032174A CN 113811301 A CN113811301 A CN 113811301A
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080032174.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·巴塔查里亚
B·比耶特
M·卡班斯基
B·岑尼
S·德巴克
M·考尔
A·基希卡尔
A·莱迪沃耶维克
A·维塔利蒂加拉米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN113811301A publication Critical patent/CN113811301A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080032174.XA 2019-05-23 2020-05-20 使用布鲁顿酪氨酸激酶抑制剂治疗舍格伦综合征的方法 Pending CN113811301A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851994P 2019-05-23 2019-05-23
US62/851,994 2019-05-23
PCT/IB2020/054754 WO2020234781A1 (en) 2019-05-23 2020-05-20 Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
CN113811301A true CN113811301A (zh) 2021-12-17

Family

ID=70918750

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080032174.XA Pending CN113811301A (zh) 2019-05-23 2020-05-20 使用布鲁顿酪氨酸激酶抑制剂治疗舍格伦综合征的方法

Country Status (23)

Country Link
US (2) US12383556B2 (https=)
EP (2) EP3972603B1 (https=)
JP (2) JP7765970B2 (https=)
KR (1) KR20220011652A (https=)
CN (1) CN113811301A (https=)
AU (2) AU2020278236C1 (https=)
BR (1) BR112021023110A2 (https=)
CA (1) CA3137271A1 (https=)
CL (1) CL2021003034A1 (https=)
DK (1) DK3972603T3 (https=)
ES (1) ES3004516T3 (https=)
FI (1) FI3972603T3 (https=)
HR (1) HRP20241584T1 (https=)
HU (1) HUE069020T2 (https=)
IL (1) IL287745B2 (https=)
LT (1) LT3972603T (https=)
MX (1) MX2021014161A (https=)
PL (1) PL3972603T3 (https=)
PT (1) PT3972603T (https=)
RS (1) RS66195B1 (https=)
SI (1) SI3972603T1 (https=)
TW (1) TWI857060B (https=)
WO (1) WO2020234781A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021023110A2 (pt) 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
MX2023008671A (es) * 2021-01-26 2023-09-25 Novartis Ag Composicion farmaceutica.
CN116782888A (zh) * 2021-01-26 2023-09-19 诺华股份有限公司 药物组合物
JP7564347B2 (ja) 2021-09-03 2024-10-08 ノバルティス アーゲー 多発性硬化症を治療するためのｌｏｕ０６４
US20250032488A1 (en) 2021-12-14 2025-01-30 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
KR102875105B1 (ko) 2023-04-03 2025-10-21 주식회사 사이알바이오 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015079417A1 (en) * 2013-11-29 2015-06-04 Novartis Ag Novel amino pyrimidine derivatives
WO2017106429A2 (en) * 2015-12-16 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
WO2017123695A1 (en) * 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
WO2019089512A1 (en) * 2017-11-06 2019-05-09 Eli Lilly And Company Btk inhibitor compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532310A (en) 2001-10-05 2007-02-23 Combinatorx Inc Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders
US10874741B2 (en) 2017-08-28 2020-12-29 Spectrix Therapeutics, LLC Compound to treat Sjogren's syndrome
KR20200074993A (ko) 2017-11-03 2020-06-25 노파르티스 아게 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
BR112021023110A2 (pt) 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015079417A1 (en) * 2013-11-29 2015-06-04 Novartis Ag Novel amino pyrimidine derivatives
WO2017106429A2 (en) * 2015-12-16 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
WO2017123695A1 (en) * 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
WO2019089512A1 (en) * 2017-11-06 2019-05-09 Eli Lilly And Company Btk inhibitor compounds

Also Published As

Publication number Publication date
IL287745B1 (en) 2025-10-01
JP2025165957A (ja) 2025-11-05
IL287745B2 (en) 2026-02-01
TWI857060B (zh) 2024-10-01
EP3972603B1 (en) 2024-09-04
EP4442321A2 (en) 2024-10-09
AU2020278236A8 (en) 2022-04-28
AU2025263830A1 (en) 2025-11-27
US12383556B2 (en) 2025-08-12
ES3004516T3 (en) 2025-03-12
EP3972603A1 (en) 2022-03-30
EP4442321A3 (en) 2025-01-01
AU2020278236C1 (en) 2026-02-26
AU2020278236B2 (en) 2025-08-07
RS66195B1 (sr) 2024-12-31
TW202110451A (zh) 2021-03-16
DK3972603T3 (da) 2024-12-02
US20220175772A1 (en) 2022-06-09
WO2020234781A1 (en) 2020-11-26
JP7765970B2 (ja) 2025-11-07
BR112021023110A2 (pt) 2022-04-12
LT3972603T (lt) 2024-12-10
PL3972603T3 (pl) 2025-02-03
FI3972603T3 (fi) 2024-12-04
CL2021003034A1 (es) 2022-09-09
PT3972603T (pt) 2024-11-26
US20250339428A1 (en) 2025-11-06
SI3972603T1 (sl) 2025-02-28
HRP20241584T1 (hr) 2025-01-31
HUE069020T2 (hu) 2025-02-28
JP2022533968A (ja) 2022-07-27
MX2021014161A (es) 2022-01-04
KR20220011652A (ko) 2022-01-28
AU2020278236A1 (en) 2022-01-06
CA3137271A1 (en) 2020-11-26
IL287745A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
TWI857060B (zh) 使用布魯頓酪胺酸激酶抑制劑治療休格倫氏症候群之方法
JP7568651B2 (ja) ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
US20250090538A1 (en) Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease
RU2824354C2 (ru) Способы лечения синдрома шегрена с применением ингибитора тирозинкиназы брутона
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
HK40110203A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
HK40061327B (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
HK40061327A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
RU2818678C2 (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
RU2847617C2 (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination